Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ...

Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in ...

Novartis NVS and AbbVie ABBV announced small M&A deals. The FDA approved the expanded use of Pfizer’s PFE cancer drug Adcetris and a tablet formulation of Roche’s R ...

Equities research analysts at William Blair issued their Q1 2025 earnings per share estimates for Incyte in a research note issued to investors on Monday, February 10th. William Blair analyst M.

The FDA accepted Regeneron’s BLA resubmission for linvoseltamab in relapsed or refractory multiple myeloma, with a decision ...

In January alone, we're expecting to see new versions of three of the best Android phones on our list. OnePlus holds an online launch event on January 7 for the global roll out of the OnePlus 13 ...

The drugmaker is stopping development of OPB-111077, an oral STAT inhibitor, for hematological cancers in the US. It also terminated several cancer drugs it was developing in Japan for cancers like ...